Novartis pays $2B to land a startup’s breast cancer drug: what does it mean for Market Access?
Novartis pays $2B to land a startup’s breast cancer drug Summary Novartis has announced a $2 billion deal to acquire Synnovation, a startup developing a PI3Kα inhibitor for the treatment